Skip to main content
Explore URMC
menu

Rituximab in Treating Patients With Mantle Cell Lymphoma

Research Question:
How does rituximab after stem cell transplant work compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission?

Basic Study Information

Purpose:
This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma.

Location: University of Rochester Medical Center
Study Reference #: CLYM17103-

Lead Researcher (Principal Investigator)

Lead Researcher:  Paul Barr

Study Contact Information

Study Coordinator: Delaney Dretto
Phone: (585) 275-5825
Email: Delaney_Dretto@URMC.Rochester.edu

Additional Study Details

Return to Search